Objective: To assess the efficacy of ultrasound treatment for mild to moderate idiopathic carpal tunnel syndrome. Design: Randomised, double blind, "sham" controlled trial with assessments at baseline, after 2 weeks' and 7 weeks' treatment, and at a follow up assessment 6 months later (8 months after baseline evaluation). Setting: Outpatient clinic of a university department of physical medicine and rehabilitation in Vienna. Subjects: 45 patients with mild to moderate bilateral carpal tunnel syndrome as verified by electroneurography. Intervention: 20 sessions of ultrasound (active) treatment (1 MHz, 1.0 W/cm 2 , pulsed mode 1:4, 15 minutes per session) applied to the area over the carpal tunnel of one wrist, and indistinguishable sham ultrasound treatment applied to the other. The first 10 treatments were performed daily (5 sessions/week); 10 further treatments were twice weekly for 5 weeks. Main outcome measures: Score of subjective symptom ratings assessed by visual analogue scale; electroneurographic measures (for example, motor distal latency and sensory antidromic nerve conduction velocity). Results: Improvement was significantly more pronounced in actively treated than in sham treated wrists for both subjective symptoms (P < 0.001, paired t test) and electroneurographic variables (motor distal latency P < 0.001, paired t test; sensory antidromic nerve conduction velocity P < 0.001, paired t test). Effects were sustained at 6 months' follow up. Conclusion: Results suggest there are satisfying short to medium term effects due to ultrasound treatment in patients with mild to moderate idiopathic carpal tunnel syndrome. Findings need to be confirmed, and ultrasound treatment will have to be compared with standard conservative and invasive treatment options.
Introduction
The carpal tunnel syndrome, caused by compression of the median nerve at the wrist, is considered the most common entrapment neuropathy. 1 Patients complain of paraesthesia (with or without numbness or pain) involving the fingers innervated by the median nerve, and a weakness of thumb abduction. Symptoms are worst at night and often wake the patient. Standard treatments include splints, local injection of corticosteroids, and surgical decompression. Benefit from non-surgical treatment, however, seems to be limited, 2 and not all patients respond to surgery. 3 4 Ultrasound treatment within an intensity range of 0.5-2.0 W/cm 2 may have the potential to induce various biophysical effects within tissue. 5 6 Experiments on the stimulation of nerve regeneration 7 and on nerve conduction by ultrasound treatment 8 9 and findings of an anti-inflammatory effect of such treatment 10 support the concept that ultrasound treatment might facilitate recovery from nerve compression. 7 However, few studies report a benefit of ultrasound treatment in the carpal tunnel syndrome under clinical conditions. 11 12 We sought to investigate the clinical efficacy of pulsed ultrasound in the treatment of idiopathic carpal tunnel syndrome by means of a rigorous, controlled clinical trial.
carpal tunnel at a frequency of 1 MHz and an intensity of 1.0 W/cm 2 , pulsed mode 1:4, with a transducer of 5 cm 2 (Sonodyn, Siemens) and with aquasonic gel as couplant. The machine was standardised initially, and the output was controlled regularly on a simple underwater radiation balance. An on/off key introduced into the transducer circuit allowed mock insonation to be given to a sham group without affecting the normal ultrasonic output when the key was turned to the "on" position. The first 10 treatments of a total of 20 ultrasound treatments were performed daily 5 times a week for 2 weeks, and the second 10 treatments twice a week for another 5 weeks.
For occasional pain relief, analgesics (usually tramadol) were allowed, but not non-steroidal or steroidal antirheumatics.
Outcome measures

Primary
Primary outcome measures for each wrist comprised (a) a sum score of subjective symptoms consisting of ratings of main complaints and sensory loss and (b) quantification of electroneurographic measurements. Main complaints were defined as complaints related to pain or paraesthesia, or to both, which the patient considered the most important ones at baseline. Severity of complaints at the clinical examination, and the worst complaints experienced within 3 days before the consultation were quantified by the study physician (GRE) by means of a coloured visual analogue scale, on which the patients could indicate their assessment along a distance of 10 cm, ranging from white ("no complaints at all") to red ("the most intense complaints I can imagine"). Sensory loss (hypalgesia or hyperpathia, or both) was assessed by means of a sharp pin wheel and compared with "normal" sensation in the fifth digit. Quantification was again by coloured visual analogue scale ("no difference at all" to "greatest possible difference").
All electroneurographic measurements were performed with a Viking II Nicolet (EMS, Madison, USA) electromyography device. Briefly, median motor nerve conduction was measured at the wrist and elbow with bipolar surface disc electrodes. Median distal motor latency was recorded with cathodes 6.5 cm apart. Antidromic sensory nerve action potentials were recorded from the wrist to the second digit, with ring electrodes placed around the proximal and distal interphalangeal joints. At least 15 sensory nerve action potentials were averaged, and antidromic sensory nerve conduction velocity was calculated as appropriate. The skin temperature of the forearm was kept constant at 32-33°C during all treatments. 15 
Secondary
Secondary outcome measures comprised (a) quantification of physical functioning and (b) the patients' general improvement. Tests of physical functioning comprised dynamometric measurements (dynamometer by Preston, New York) of hand grip and finger pinch strength. The patients' positioning was standardised, and the average force of three consecutive trials was calculated. The patients rated their overall change at the end of the treatment series on a five point ordinal scale (1 = free of symptoms, 5 = much worse).
Other factors
At each appointment the patients rated their main complaint without being reminded of the ratings they had made at previous appointments. Drugs taken for pain relief were registered and side effects of the ultrasound treatment reported.
Electrophysiological measurements and clinical examinations were performed before the first treatment session, after 10 sessions (week 2), and after the last session (week 7). A follow up was performed six months later (8 months after baseline evaluation). After the follow up examination the treatment code was broken, and patients were either discharged or offered an alternative treatment.
Sample size
A sample size calculation was performed based on the assumptions that the main outcome measurement (changes in sum score between baseline and end of treatment on visual analogue scale) is continuous in nature, fairly normally distributed, and that an additional improvement in the intervention side of 10 percentage points (standard deviation = 15 percentage points) is considered clinically relevant. If the incidence of the carpal tunnel syndrome on one wrist could be considered completely independent from the incidence on the other wrist, 36 independent observations in each group would be necessary to detect that difference at the 5% level ( = 0.05) with an 80% chance ( = 0.2). Synchronicity of the carpal tunnel syndrome in both wrists happens in about one third of all cases, but to our knowledge no evidence exists that the natural course of symptoms goes strictly in parallel in these cases. In addition, systemic interventions that would probably affect both wrists, such as pain killers, were among the exclusion criteria. Taken together, 45 to 50 independent observations in each group might be a sensible estimate. 
Assignment
A randomisation list was produced with a random number generator of a popular spreadsheet program (Lotus Symphony). After the eligible patients had been enrolled, an ultrasound therapist not involved in the treatment allocated the dominant wrist of each consecutive patient to ultrasound or sham treatment (the patient's other wrist received the other treatment) by means of sequentially numbered sealed opaque envelopes containing the group allocation (active or sham). This therapist was the only person aware of treatment allocation during the trial.
Blinding
The patients, GRE, and the therapists who delivered the ultrasound treatment were all unaware of the treatment allocation. Only the therapist who was in charge of group allocation switched the ultrasonic generator to the respective modes before each treatment session (see above). This procedure allowed blinding of both the patients and the therapists delivering the treatment. Intensity of ultrasound treatment was below sensitivity threshold.
Results
Baseline evaluation
Forty five patients with bilateral carpal tunnel syndrome (90 wrists) fulfilled all inclusion criteria; 11 (24%) of these patients discontinued treatment after randomisation (8 patients early after randomisation because of non-compliance in keeping appointments, and 3 patients because of excessive pain requiring additional therapeutic measures). Thus 34 patientsthat is, 34 actively treated and 34 sham treated wristscompleted the study. Their characteristics did not differ from the original 45 patients in the study. Thirty of them (67% of the initial 45 patients) completed a follow up at 6 months.
The wrists were similar in terms of the duration of current episodes of main complaints regardless of randomisation group (table 1) . There were slight group imbalances at baseline. Most complaints in the actively treated group were significantly more severe (P = 0.05, Wilcoxon test) when rated on the visual analogue scale. Baseline differences were also present in the mean score of physical functioning and strength of hand grip, whereas finger pinch was comparable.
Other subjective symptoms-for example, scores of main complaints, sensory loss, and the mean score of all subjective symptoms-were similar at baseline. Electroneurography, motor distal latency, peak to peak amplitude, and antidromic sensory nerve conduction velocity did not differ significantly between wrists. Table 2 and figure 2 show longitudinal changes of subjective symptoms. Improvement in the mean score of all ratings of subjective symptoms was significantly more pronounced in the actively treated wrists at week 2 (P < 0.008), at the end of treatment (P < 0.0001), and at the 6 month follow up (P < 0.0001).
Effect of treatment
Subjective symptoms
Satisfactory improvement or complete remission of symptoms was observed in 68% (23/34) of the wrists receiving active treatment versus 38% (13/34) of those receiving sham treatment (P < 0.001; relative risk reduction 48%) at the end of the treatment series, and in 74% (22/30) versus 20% (6/30) (P < 0.001; 67%) at 6 months' follow up. . Similar significant changes in the velocity of sensory nerve conduction were observed at the end of treatment and at 6 months' follow up with active treatment, whereas velocity remained unchanged with sham treatment (P < 0.0001 between groups).
Physical functioning
Hand grip and finger pinch strength had improved significantly with active treatment at the end of treatment and at 6 months' follow up (table 2).
Other measurements
Patients' ratings of overall improvement at the end of treatment significantly favoured active over sham treatment (Mann-Whitney U test P = 0.002). Good or excellent treatment results were stated by 76% (26/34) of the patients for actively treated wrists versus 32% (11/ 34) for sham treated wrists.
At 6 months' follow up 28 patients showed an unsatisfactory outcome (9 actively treated and 19 sham treated wrists) and were offered further treatment. Subsequently 13 patients were offered ultrasound treatment and splints for their sham treated wrists, and 10 wrists (3 sham treated) were injected with steroids. Surgical relief of the carpal tunnel syndrome was planned for 5 patients (3 sham treated wrists).
Average consumption of analgesics during treatment and follow up phase was low: 8 out of the 34 patients occasionally took analgesics, and three patients were off work. No side effects due to ultrasound treatment were reported.
Discussion
An increase in pressure in the carpal tunnel is usually caused by non-specific flexor tenosynovitis. 16 Chronic focal compression of a nerve trunk can cause focal demyelination by mechanical stress deforming the myelin lamellae. Ischaemia also plays a pathogenic role in the carpal tunnel syndrome. It could account for intermittent paraesthesia that occurs at night or with wrist flexion. 2 The carpal tunnel syndrome is often observed bilaterally. Symptoms are usually markedly worse on one (mostly the dominant) side.
Conservative treatment approaches seem to offer clear advantages over surgical treatment of the carpal tunnel syndrome. Recent studies have confirmed short term effects of steroid injections into the carpal tunnel, with modest or complete pain relief in up to 92% of the patients, although long term recurrence rates seem variable. [17] [18] [19] Potential adverse effects to nerves and tendons with repeated injections have limited the value of this treatment. 20 21 Palmar wrist splints worn at night seem suitable only when symptoms are mainly nocturnal, 22 and ergonomic strategies have not yet been evaluated.
The findings of the present study confirm preliminary data that ultrasound treatment may facilitate recovery from the carpal tunnel syndrome. 11 12 Given the favourable response rate of 68% of patients at the end of treatment, ultrasound treatment may be similar in effectiveness to steroid injections or wrist splinting; improvements persisting for at least 6 months in most patients might even suggest the potential superiority of ultrasound treatment.
Serial ratings by patients of overall improvement suggest that ultrasound treatment would be best administered every day. Frequent treatment, however, is time consuming (as seen by the relatively high drop out rate in our study), but ultrasound treatment could be performed by compliant patients at home.
According to the pathophysiology of the carpal tunnel syndrome, ultrasonography might elicit antiinflammatory and tissue stimulating effects, as already shown experimentally 23 and in recent clinical trials. 10 24
Conclusion
Our trial suggests that ultrasound treatment has good short term effectiveness and even yields satisfying medium term effects in patients with mild to moderate idiopathic carpal tunnel syndrome. Further research is required to confirm independently these findings, to evaluate optimal treatment schedules with this method, and to investigate whether ultrasound treatment or one of the non-surgical treatments alone or in combination is superior, or whether early decompression may provide better long term results with fewer eventual neurological deficits.
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x Chronic entrapment of the median nerve at the wrist (the carpal tunnel syndrome) is probably the most common peripheral nerve lesion
x No satisfactory conservative treatment is available at present
x Twenty sessions of ultrasound treatment show good short and medium term efficacy in patients with bilateral, mild to moderate forms of the carpal tunnel syndrome
x Optimal treatment schedules of ultrasound treatment alone or in combination with other non-surgical treatments await elucidation
Introduction
The measurement of health is central to the evaluation of health care. By observing the extent of changes in health the benefits and disbenefits of health care for both patients and groups of patients can be evaluated; over the past 25 years several generic measures of health have been developed for use in this way. [1] [2] [3] [4] [5] [6] [7] [8] These instruments were designed for use as general purpose measures of health, independent of diagnostic categorisation or disease severity. Information based on such measures is useful for establishing the degrees of morbidity in the community, enabling different population subgroups to be compared, which would help in assessing health needs or in informing those responsible for allocating health resources. Periodic reassessment of health could provide important data on the extent of any changes in the health of a populationfor example, the extent to which the population is achieving national targets for health. If such standardised information was also routinely collected on individual patients it would provide a simple means of evaluating the outcomes of their health care.
We report on a study in which the EuroQoL EQ-5D questionnaire 9 was fielded in a survey of the population of the United Kingdom, conducted as part of a wider study of practical ways of measuring health related quality of life.
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Subjects and methods
EQ-5D questionnaire
The EQ-5D questionnaire is a generic measure of health status developed by the EuroQoL Group, an international research network established in 1987 by researchers from Finland, the Netherlands, Sweden, and the United Kingdom. The EQ-5D questionnaire defines health in terms of five dimensions: mobility, self care, usual activities (work, study, housework, family, or leisure), pain or discomfort, and anxiety or depression. Each dimension is subdivided into three categories, which indicate whether the respondent has no problem, a moderate problem, or an extreme problem (appendix). Combinations of these categories define a total of 243 health states. The EQ-5D questionnaire comprises two pages; on the first page respondents record the extent of their problem in each of the five dimensions and on the second page they record their perception of their overall health on a visual analogue scale (0 denoting the worst imaginable health state and 100 denoting the best imaginable health state). The validity and reliability of the EQ-5D questionnaire have been tested, [11] [12] [13] as has its application in a range of patient groups. [14] [15] [16] Since the original survey reported here, the EQ-5D questionnaire has been fielded in three national surveys, including the English national health survey-an interview-based survey of about 16 000 people. The EQ-5D questionnaire has also been used in population surveys in Spain, Germany, and Canada.
Survey design and methods
Members of the public aged 18 and over were interviewed as part of a national survey. No upper age limit was stipulated. The sample was based on addresses in England, Scotland, and Wales, selected by postcode. 17 Eighty postcode areas were chosen, proportionately to the number of addresses in each area, after these areas had been stratified by regional health authority, socioeconomic group, and population density. Seventy six addresses were selected from each postcode area, yielding a total of 6080 addresses. At each of these addresses one adult aged 18 or over was selected using a Kish grid. 18 Individuals in institutions, hostels, care homes, or bed and breakfast accommodation were excluded from the sample. Of the selected addresses, 12% were unproductive as they were non-residential, empty, or untraceable. The final sample comprising 3395 subjects was representative of the general population with respect to age, sex, and social class. During the interview, respondents completed the EQ-5D questionnaire and provided information on age, sex, marital state, education, employment, housing tenure, and smoking behaviour. The interviews took place during the last quarter of 1993.
Analysis mainly compared the differences between the population subgroups. It was hypothesised that more health problems would be reported with increasing age, with lower social class, for those registered sick or disabled, and for smokers. 2 Tests were used for the analysis of the descriptive profile data, and Student's t test was used to test for subgroup differences in the visual analogue scale data.
Results
A moderate problem on at least one dimension was reported by 42% of respondents, whereas only 6% of respondents reported any extreme problem (table 1) . Problems were most often recorded in the pain or discomfort dimension. In subsequent analyses, moderate and extreme categories of each dimension were combined.
The mean state of health recorded on the visual analogue scale was 82.5 (SD 17).
Health and age
The rates of reported problems increased significantly with age (P < 0.001) for all dimensions (table 2) ; an exception to this general pattern was the anxiety/ depression dimension, which peaked at 28% of respondents aged 60 to 69 and then decreased slightly. Figure 1 shows the mean visual analogue scale values for each age group and the 95% confidence interval. The mean value decreased from about 87 in the youngest age group to 72 in the oldest age group. Mean values did not differ significantly in the 20 to 49 age range but decreased significantly for respondents aged >50 (P < 0.001).
Health and sex
Women aged >70 tended to report higher rates of problems than did men of the same age (table 2) . A systematic difference in rates was found across all age groups on the anxiety/depression dimension, with women reporting significantly higher rates than men (P < 0.05). No significant differences were found in the visual analogue scale scores for men and women.
Health and marital status
Respondents who were widowed, separated, or divorced reported significantly more problems on all five dimensions (P < 0.001). Scores on the visual analogue scale for this group were also significantly lower than for respondents living alone or for those with a partner (means 77, 84, and 84 respectively, P < 0.001).
Health and social class
After the effects of age were controlled for, there were significant differences in the rates of reported problems when respondents were grouped according to social class (table 3) . 
Fig 1 Mean self rated health status of respondents
Rates of reported problems from respondents in social classes III and IV were between 20% and 120% higher than rates in respondents from social classes I and II; the largest differences were for the pain/ discomfort (P < 0.01) and anxiety/depression (P < 0.01) dimensions. Rates did not differ significantly for the mobility and self care dimensions. Figure 2 shows that respondents from social classes I and II had consistently higher levels of reported health as measured by the visual analogue scale than respondents from the two other social classes. Respondents from social classes I and II had a 5 point advantage on the visual analogue scale over respondents from social classes IV and V of the same age group. The difference was significant for all age groups except for respondents aged 40 to 49 years. The mean scores on the visual analogue scale for respondents from social classes I and II remained above the level of the youngest respondents from social classes IV and V until the 50 to 59 age group.
Health and education
When respondents were classified by education rather than by social class, a similar pattern of differences emerged. Respondents who had received higher or further education reported significantly lower rates of problems with mobility (P < 0.05), usual activities (P < 0.05), pain/discomfort (P < 0.01), and anxiety/ depression (P < 0.01) than did those who had received no education after leaving school. A similar pattern was seen on the visual analogue scale, with significantly higher scores reported for those who had received higher or further education (P < 0.001).
Health and economic status
Significantly higher rates of problems were reported by respondents who were unemployed, sick or disabled, or retired, compared with those in employment or full time education (P < 0.001) (table 4). Rates of reported problems for unemployed people were almost twice those of respondents in a salaried job.
When respondents were grouped according to housing tenure, significantly higher rates of problems were recorded on all the dimensions for those living in rented property compared with owner occupiers.
The mean scores on the visual analogue scale of people in work or of people who were studying was significantly higher than for people who were unemployed (87.5 and 82.0 respectively, P < 0.001). Similarly, the scores of owner occupiers were significantly higher than for people who rented their accommodation (85.1 and 77.2 respectively, P < 0.001). 
Health and smoking behaviour
Respondents who smoked reported significantly higher rates of problems than non-smokers on all dimensions. Non-smokers also recorded significantly higher scores on the visual analogue scale than respondents who smoked (83.4 and 80.4 respectively, P < 0.001).
Analysis of variance
Analysis of variance was used to investigate the collective influence of background variables. With the score on the visual analogue scale as the dependent variable and age as a covariate, a main effects model indicated a significant contribution for education (P < 0.01), employment (P < 0.001), and smoking behaviour (P < 0.001). Housing tenure, marital status, and social class were not significant variables in this model.
Disability rates from other national surveys
Respondents who reported any problem in any dimension could be distinguished from respondents who reported no problems whatsoever. This dichotomy can be used to form an arbitrary definition of disability, enabling data to be compared with the findings of other surveys. The general household survey incorporates questions on longstanding illness and recent interference with usual activities. 19 The responses to these questions are combined to give rates of limiting longstanding illness which are published annually. The disability survey by the Office of Population Censuses and Surveys conducted in 1985 included a questionnaire comprising 10 categories: locomotion, reaching and stretching, dexterity, seeing, hearing, personal care, continence, communication, behaviour, and intellectual functioning. 20 The rates of disability in people grouped into five year age groups were reported in this survey. 20 These data were plotted against disability rates determined from our survey (fig 3) . Disability rates based on responses to the EQ-5D questionnaire were 20% to 25% higher than rates from the general household survey for all age groups and about 30% to 40% higher than the 1985 disability survey, until the age of 80.
Discussion
This survey provides an important insight into the health status of the population of the United Kingdom at any one time. Although extreme problems with mobility and self care were rarely reported in this survey, there was a high level of reported problems with pain or discomfort. Over 50% of respondents aged >70 and about 20% of the youngest respondents reported some problem in this dimension. This finding has important implications. Pain does not seem to be a dimension of interest in a national disability survey despite being widely experienced in the community. The omission of a pain category means that it is assigned a zero weight, despite good evidence that it has a powerful influence on society's valuations of states of health. 21 These factors combine to disadvantage a significant proportion of the general population.
Significant differences were found between population subgroups with respect to age, social class, marital status, employment, education, and smoking behaviour. These findings compare with findings reported elsewhere. [22] [23] [24] Disability rates based on the EuroQoL classification reflected similar trends to those seen in the general household survey and surveys of the Office of Population Censuses and Surveys, although rates in these surveys were somewhat lower as they were based on a narrower definition of disability.
Population averages
The representativeness of the survey suggests that the results are indicative of the average health status in the general population of the United Kingdom, although it should be borne in mind that sampling was limited to individuals living in the community and tended to exclude people who had extreme problems with mobility or with self care and therefore likely to be dependent on others for their daily needs. Current investigation of specific patient groups-for example, people attending their general practice surgeriesreveals a wider distribution of reported problems. Thus, to the extent that this survey excluded people who were likely to yield responses indicating more severe problems, the results may well underestimate the health related quality of life of the general population. 
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Fig 3 Disability rates from three national surveys
Our data can be treated as descriptive population "norms." As such, they could provide baseline values for monitoring variations in health for specific population groups, particularly if this information was also linked to local epidemiological data. In aggregate form, such information could be used to complement national targets by providing a measure based on health status rather than mortality. The capacity of the EQ-5D questionnaire to generate quantifiable and usable information on the health status of a population led to its inclusion in the 1996 health survey for England. 25 
Measuring outcomes
However, it is the measurement of change in health status for which the need is greatest. There can be few circumstances in which healthcare workers are not concerned with the measurement of outcome, and the EQ-5D questionnaire provides the capacity to measure change in health status, and hence outcomes, in a simple standardised way. The information on self reported problems recorded on the first page of the EQ-5D questionnaire identifies a unique health status for which there is a corresponding index value based on the views of the general population. 21 Changes in health status and the value of that change can be used to quantify outcomes for clinical and economic evaluation; the latter role was recommended for the EQ-5D questionnaire in a report commissioned by the United States Department of Public Health. 26 There is "an increasing consensus regarding the centrality of the patient's point of view in monitoring medical care outcomes," 6 and the EQ-5D questionnaire has the obvious potential to contribute to that process. The national survey data reported in this paper show what can be achieved by using an uncomplicated instrument for measuring health status. The further exploitation of its potential is open to us all.
Survey work for the 1993 survey was conducted by Social and Community Planning Research, and we thank the trained fieldwork staff for their help in the collection of the data.
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Introduction
A recent epidemiological study reported an excess risk of depression requiring pharmacological treatment after treatment with calcium channel blockers and angiotensin converting enzyme inhibitors but not after treatment with digoxin, anti-arrhythmics, nitrates, diuretics, or blockers. 1 There have also been case reports suggesting depression [2] [3] [4] [5] as well as psychosis 6 after treatment with calcium channel blockers. As depression may promote suicide we investigated possible ecological associations between suicide rates and the rates of use of eight cardiovascular drug groups in 152 Swedish municipalities. In addition, we investigated the risk of suicide in users and non-users of calcium channel blockers who had purchased prescription drugs mainly used to treat hypertension.
Methods
This report concerns two different studies: firstly, an ecological study with data from Swedish municipalities on rates of suicide and rates of use of eight groups of cardiovascular drug groups; secondly, the hypothesis generated by this study tested in a cohort study on historical data from users of different antihypertensive drugs.
The ecological study
Sweden is administratively divided into 284 municipalities. Suicide rates for men and women standardised for age for these municipalities during the 5 year period 1989-93 were obtained from the epidemiological centre of the Swedish Board of Health and Welfare. Data on incidence of cause specific mortality were missing for eight municipalities. Data on suicide mortality (ICD-9 (international classification of diseases, 9th revision), codes E950-E959 and E980-E989) were available for 152 municipalities in which the expected number of people committing suicide during the 5 year period was more than five men and five women, as assumed from the overall suicide rates in Sweden.
Rates of use of cardiovascular drugs by outpatients, defined by the Anatomical Therapeutical Chemical (ATC) classification 7 and expressed as pharmacy dispensed numbers of defined daily doses per 1000 inhabitants per year, were obtained from Apoteksbolaget (the Swedish Corporation of Pharmacies) for each of the 152 municipalities during each of the years 1989-93. The geometric means of the annual rates of use were used in the calculations.
The rates of use of eight cardiovascular drug groups-diuretics, blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, lipid lowering agents, low dose aspirin, nitrates, and cardiac glycosides-were correlated with suicide rates by using Pearson's correlation coefficient. Partial correlation coefficients between suicide rates and rates of use of the cardiovascular drug groups were assessed to estimate a correlation coefficient for each drug group independent of variations in the rates of use of the seven other groups to use as a proxy for cardiovascular disease prevalence. All tests were two sided.
The cohort study
Data on individual prescription drug use in a municipality located in mid-eastern Sweden (population about 20 000 in 1989) have been compiled and studied since the 1970s. All prescription drugs purchased by residents from pharmacies within the municipality are registered according to the ATC system. 7 For the purpose of the present study all inhabitants of the municipality were identified who during 1988 or 1989 had purchased cardiovascular medications with ATC codes (in 1988 and 1989) C02 (centrally acting antiadrenergic agents, ganglion blocking antiadrenergic agents, peripherally acting antiadrenergic agents, calcium channel blockers, angiotensin converting enzyme inhibitors), C03 (diuretics), and C07 ( blockers). ATC codes for calcium channel blockers and angiotensin converting enzyme inhibitors were later changed to C08 and C09, respectively. The subjects were classified as users or non-users of calcium channel blockers. Mortality data for the cohort until the end of 1994, including the cause of death, were derived from the Swedish mortality register. 8 Deaths from suicide were defined by the ICD-9 codes E950-E959 and E980-E989. The codes E980-E989 include cases with uncertain intention for suicide. Data on purchased medications and cause of death were linked by the Swedish personal identification number.
Differences in risk of suicide were evaluated by the Kaplan-Meier method and the log rank test. Multivariate adjustments for differences in age and sex were performed with the proportional hazards method. All P values are two sided.
Results
The ecological study The number of suicides in the 152 municipalities during the 5 year period ranged from 5 to 652. The total number of suicides in the municipalities during this period was 5648. The total population was 7.3 million, and the mean (range) municipality population was 48 042 (13 722 -679 364) in 1991. Age adjusted suicide rates varied from 0.76 to 3.69 deaths per 10 000 inhabitants per year. The mean (SD) suicide rate for the 152 municipalities was 2.06 (0.49) suicides per 10 000 inhabitants per year. The rates of use were 79.7 defined daily doses per 1000 inhabitants per day for diuretics, 36.8 for blockers, 22.5 for calcium channel blockers, 20.4 for nitrates, 16.0 for angiotensin converting enzyme inhibitors, 15.3 for cardiac glycosides, 9.4 for low dose aspirin, and 2.9 for lipid lowering agents.
The correlation coefficients for the relations between rates of drug use and rates of suicide are given in table 1. Except for angiotensin converting enzyme Table 1 Correlation coefficients for rates of use of cardiovascular drug groups and rates of suicide in 152 Swedish municipalities, 1989-93 inhibitors, the rates of use correlated significantly with the suicide rates. The highest correlation coefficient was seen for calcium channel blockers (r = 0.36, P < 0.001) (figure 1). After adjustment for differences in the rates of use of the other drug groups, only the rates of use of calcium channel blockers correlated significantly with the suicide rates (r = 0.29, P < 0.001) (table 1). Additional adjustment for the proportion of men living in the municipality did not alter this result.
The rates of use of two predominantly cardioselective and two predominantly vasoselective calcium channel blockers also correlated significantly with suicide rates (table 2). After adjustment for the rates of use of the seven other types of cardiovascular drug groups, the use of both dihydropyridine and benzothiazepine derivatives remained significantly correlated with suicide rates. When we adjusted for differences in use of the seven other cardiovascular drug groups, the correlation coefficient was 0.21 for dihydropyridine derivates and 0.18 for benzothiazepine derivatives. The rates of use of diltiazem had the closest correlation with suicide rates (table 2).
The cohort study
In all, 3397 patients were identified as purchasers of drugs with ATC codes C02, C03, and C07 in 1988 and 1989. Of them, 617 (18.2%) were classified as users of calcium channel blockers (nifedipine, verapamil, diltiazem, and felodipine) and 2780 (81.8%) as non-users. During the follow up, from the date of purchase until the end of 1994, five users of calcium channel blockers (three men and two women, one with uncertain intent) and four non-users (three men and one woman, none with uncertain intent) committed suicide. The 7 year suicide risks were 9.7 and 2.2 per 1000 persons for calcium channel blocker users and non-users, respectively. The difference in suicide risk was significant (P = 0.002.) The average annual absolute risk associated with use of calcium channel blockers was therefore 1.1 suicides per 1000 persons. After adjustment for differences in age and sex the relative risk among users versus nonusers was 5.4 (95% confidence interval 1.4 to 20.5). Figure 2 illustrates the cumulative suicide rates during follow up of users and non-users of calcium channel blockers.
Discussion
In the past several groups of cardiovascular drug have been associated with depressive disorders. As suicide is a serious consequence of depression, the current studies were undertaken to evaluate the possible influence of widely used drugs on risk of suicide. The correlation between use of calcium channel blockers and suicide rates found in the ecological study led us to design a cohort study to test if, among users of antihypertensive drugs, subjects using calcium channel blockers had a higher risk of suicide than subjects not using calcium channel blockers.
Diltiazem, 2 nifedipine, 3 and verapamil 4 have been associated with depressive disorders in case reports and also in a previous epidemiological study that used data on individual prescriptions of calcium channel blockers and antidepressants. 1 The two current studies imply that calcium channel blockers may also promote suicide. In the ecological study the estimated correlation suggests that about one tenth of the intermunicipality variation in risk of suicide is related to the use of calcium channel blockers. In the cohort study the suicide risk in users of calcium channel blockers adjusted for sex and age was fivefold compared with the risk in non-users treated with other antihypertensive agents.
Clinical trials have a limited ability to detect infrequent or late adverse effects or adverse effects resulting in common symptoms. They also often use a number of inclusion and exclusion criteria, thus reducing their generalisability. Studies with a long follow up and studies encompassing the whole population are therefore needed.
In contrast with most clinical trials the current cohort study included all identified users of the study drugs. Consequently the generalisability of the study is high. In the ecological study low populated municipalities with few expected suicides were excluded, so the influence from extreme rates in combination with small number of events was avoided.
In Sweden, as in most other countries, men have a higher incidence of suicide than women. Men are also more likely to be prescribed a calcium channel blocker (unpublished data on file). In our cohort study the estimated rates of suicide were adjusted for differences in age and sex, and, in the ecological study, the suicide rates were adjusted for differences in age. Additional adjustment of the ecological correlations for the proportion of men in the municipalities did not affect the results (no data given), thus we can eliminate age or sex differences as confounders.
Comorbidity such as cardiovascular diseases might have promoted depressive disorders and suicide. In the ecological study this problem was dealt with by adjusting the correlation for each tested cardiovascular drug group with the rate of use of the seven other drug groups. In the cohort study all subjects were treated with antihypertensive drugs. It follows that although no detailed clinical data were available, users and non-users of calcium channel blockers most probably had similar medical backgrounds.
Populations with a high prevalence of cardiovascular diseases also have a high suicide risk. In the ecological study the rates of use of all but one evaluated cardiovascular drug group also correlated significantly with the suicide rates before adjustment for the rates of use of the other drug groups. After adjustment, however, only the rate of use of calcium channel blockers was significantly and positively correlated with suicide rates (see table 1 ). Accordingly, the increased suicide risk linked to use of calcium channel blockers would seem independent of cardiovascular comorbidity.
Links with depression
Calcium channel blockers are often prescribed to treat angina pectoris. If angina pectoris causes depression, this might form a link to suicidal behaviour. Nitrates are also prescribed to treat angina pectoris, however, and the rates of use of nitrates did not correlate with suicide rates when we adjusted for the rates of use of other cardiovascular drug groups. Neither did the use of angiotensin converting enzyme inhibitors, often prescribed to patients with diabetes, correlate with suicide rates. Thus, it seems unlikely that the presence of angina pectoris or diabetes help to explain the linking of calcium channel blockers to depression and increased suicide risk.
Other reasons to prescribe calcium channel blockers might have been greater difficulty in achieving control of blood pressure or adverse effects from other antihypertensive drugs. Again, it is not very likely that such circumstances have enough penetrative power to link calcium channel blockers to depression and suicide risk.
In the late 1980s blockers were suspected of inducing depression. 9 Therefore, other antihypertensive or antiangina drugs might have been chosen for patients with depression. If calcium channel blockers were used particularly often in depressed patients, an increased suicide risk would appear in users of calcium channel blockers even though the drugs per se would not promote depression and suicide. To behave as a confounder, however, the confounding variable has to be substantially correlated to the tested exposition as well as to the outcome. Therefore, to achieve a high increase in suicide risk by confounding from selective prescribing of calcium channel blockers to depressed patients, most depressed patients with increased risk of suicide and few non-depressed patients should have been prescribed calcium channel blockers. Only about half of depressed patients are correctly diagnosed by their primary care physicians, 10 however, and use of calcium channel blockers is also obviously common in patients without depression. In the cohort study population patients were classified as users and non-users of calcium channel blockers at the time of inclusion. Some of the former might have stopped taking calcium channel blockers shortly after inclusion and some non-users might have been prescribed calcium channel blockers after inclusion. Moreover, both studies take drugs purchased from pharmacies into account. It is not certain that each purchased drug was used, and some inhabitants may not have purchased drugs from pharmacies in their home municipality. Provided that the misclassification was independent of the outcome, however, misclassification of exposure would probably have resulted in underestimation of the true association.
One way to interpret the results of the ecological study is to assume that most, if not all, cardiovascular agents have some depressive effect, calcium channel blockers being most prominent. As the studied cardiovascular agents were very heterogeneous, however, a common effect on mood is unlikely.
In contrast with most other cardiovascular agents, calcium channel blockers influence secretory and contractile mechanisms in many different types of cells. Because of their lipophilic properties they easily penetrate the blood-brain barrier. Hence they have access to and may interfere with neurones and receptors involved in the regulation of mood. As calcium channel blockers differ in selectivity and in kinetics their influence on the central nervous system may vary. In the ecological study, however, the rates of use of both dihydropyridine and benzothiazepine derivatives correlated significantly and those of phenylalkylamine derivatives non-significantly with suicide rates after adjustment for the rates of use of other cardiovascular drug groups. Hence it seems likely that calcium channel blockade per se is involved in the increased risk of suicide. A calcium channel effect of dihydropyridines in affective disorders has also been suggested previously. 5 In conclusion, use of calcium channel blockers may increase risk of suicide. A depressive effect of these drugs has been suggested and may constitute a link with risk of suicide. The consequences of treatment with calcium channel blockers should be further inves- We investigated whether it also predicted cardiac death in diabetic patients.
Subjects, methods, and results
The study group of 182 patients with non-insulin dependent diabetes mellitus (103 men; mean age 52.8 (SD 8.5) years) represented the Dundee cohort of the United Kingdom prospective diabetes study, which was recruited between 1982 and 1988. Patients were followed up for a mean of 10.3 (1.7) years. The inclusion and exclusion criteria of the study have been reported elsewhere. Patients with overt cardiac disease at baseline were excluded. A single observer (AAON) measured QT intervals as described previously.
1-3 Cardiac death was mostly classified at the coordinating centre in Oxford, using the codes of the international classification of diseases, ninth revision. All analysis was done by Cox regression analysis, with cardiac death as the sole end point. We used forward stepwise analysis, each time using all three QT variables along with age, systolic blood pressure, sex, smoking, blood glucose concentration, and antihypertensive drug. As a result, we identified age, systolic blood pressure, sex, diuretics, and all QT variables as the potentially important variables. Finally we fitted the regression using these four variables with each of the three QT variables.
In those who had a cardiac death, the mean time of death after the baseline electrocardiogram was 7.3 (3.2) years; after the 3 year electrocardiogram it was 4.9 (2.3) years and after the 6 year electrocardiogram 3.8 (1.0) years. The table shows that QTc max, QTc dispersion, and QT dispersion are all highly significant and independent predictors of cardiac death at baseline, at 3 years, and at 6 years. In multivariate analysis they outperformed all other predictors.
Comment
Our main finding was that QT dispersion, QTc dispersion, and QTc max are excellent predictors of cardiac death in patients with non-insulin dependent diabetes mellitus. QTc interval analysis has two major advantages over other possible ways of stratifying risk in patients. Firstly, measurements of QTc interval are easily obtained with a non-invasive routine test: other potential predictors of cardiac death often require extra testing with specialised equipment. Secondly, comparisons between QTc dispersion and microalbuminuria suggest that QTc dispersion is a better predictor of cardiac death. 4 A QTc dispersion > 78 ms at year 6 in this study had 100% sensitivity and 90% specificity, giving an odds ratio of 9.0, whereas the odds ratio for microalbuminuria was only 1.8 in a recent overview. 5 The question arises why analysis of QT interval should be able to predict cardiac death. QT dispersion may be a composite term reflecting electrical inhomogeneity as a result of ischaemia, left ventricular dilatation, left ventricular hypertrophy, cardiac fibrosis, and autonomic neuropathy. Each one of these individually confers increased cardiac risk, and this may be why QT dispersion, as a composite of them, is highly predictive of cardiac death. The clinical value of analysing the QT interval may therefore be that it could be used as a screening test to select diabetic patients for more extensive cardiac investigations. Importantly, the time between measuring a prolonged QT interval and the subsequent cardiac death is many years, which provides ample opportunity to intervene.
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Methods and results
We checked in databases, reference lists, and gastroenterology journals for any studies published before January 1997 that assessed H pylori infection after surgery for peptic ulceration. Studies were included if they provided information on the indication for surgery and the type of surgery. We tabulated the type of surgery, the mean interval between surgery and testing 
